Journals / Turkish Neurosurgery / 2011 / Cilt: 21 - Sayı: 4

Blefarospazm ve hemifasiyal spazmda botulinismus toksininin iki farklı formülünün karşılaştırılması

Comparison of two different formulations of botulinum toxin a for the treatment of blepharospasm and hemifacial spasm

Pages
625–629
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

ConclusIon: The two preparations were both simple and effective for the patients with blepharospasm and hemifacial spasm.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AIm: Aim: To confirm and compare the therapeutic efficacies and adverse effects of Chinese botulinum toxin type A (CBTX-A, Lanzhou Biological Products Institute, China) and current Botox (Allergan Inc., CA, USA) in the treatment of blepharospasm (BS) and hemifacial spasm (HFS).
📊
Key Findings & Data:Ma terIal and Methods: We performed an open, prospective, comparative trial comparing CBTX-A and Botox for the treatment of BS and HFS in 273 patients since 2006. 107 patients were treated with current Botox and166 with CBTX-A, with the age, disease durations and severity of spasm matched.
💡
Conclusion & Impact:ConclusIon: The two preparations were both simple and effective for the patients with blepharospasm and hemifacial spasm.
🔬Design:Research Article
📍Scope:2006 Verileri
⚙️Variables:Domain Parameters

Abstract

AIm: Aim: To confirm and compare the therapeutic efficacies and adverse effects of Chinese botulinum toxin type A (CBTX-A, Lanzhou Biological Products Institute, China) and current Botox (Allergan Inc., CA, USA) in the treatment of blepharospasm (BS) and hemifacial spasm (HFS). Ma terIal and Methods: We performed an open, prospective, comparative trial comparing CBTX-A and Botox for the treatment of BS and HFS in 273 patients since 2006. 107 patients were treated with current Botox and166 with CBTX-A, with the age, disease durations and severity of spasm matched. The patients enrolled were followed up for 6 months. Results: There were no significant differences in the clinical effects of the two preparations, including the onset of response, peaked effect time and duration of effects (p>0.05). The Cohen scores showed a significant reduction after BTX-A injections. Considerable improvement of symptoms for the BS and HFS patients was observed 7days, 4weeks, 12weeks, and 24 weeks after the injection with either current Botox or CBTX-A (p<0.05). There was no significant difference in the effectiveness rate for both HFS patients and BS patients between CBTX-A group and Botox group (p>0.05). No statistical differences were noted in adverse reactions between them (p>0.05). ConclusIon: The two preparations were both simple and effective for the patients with blepharospasm and hemifacial spasm.

Özet

AMAÇ: (CBTX-A, Lanzhou Biological Products Institute, China) Blefarospzm ve hemifasial spazmda Çin üretimi (CBTX-A, Lanzhou Biological Products Institute, China) Botulinismus toksininin (Tip A) etkinliği ile Amerikan üretimi Botulinismus toksininin (Allergan Inc., CA, USA) etkinliği karşılaştırılmıştır. YÖNTEM ve GEREÇler: Prospektif karşılaştırmalı çalışmada Çin üretimi (CBTX-A, Lanzhou Biological Products Institute, China) Botulinismus toksininin (Tip A) etkinliği ile Amerikan üretimi Botulinismus toksininin (Allergan Inc., CA, USA) etkinliği bleforaspazmı veya hemifasial spazmı olan 273 hasta üzerinde 2006 yılından başlanarak incelenmiştir. Hastalardan 107’sine Amerikan üretimi Botulinismus toksini (Allergan Inc., CA, USA) verilirken 166 hastaya Çin üretimi Botulinismus toksini (CBTX-A, Lanzhou Biological Products Institute, China) blefarospazm ve hemifasial spazmda tedavi için kullanılmıştır. Hastaların yaşı, hastalığın süresi ve spazmların şiddetleri tedavi sonrası 6 ay boyunca takip edilmiştir. BULGULAR: Etkinin başlama süresi, etkinin en üst düzeye ulaştığı dönem ve etkinliğin süresi göz önüne alındığında iki farklı madde arasında anlamlı bir fark saptanmadı (P>0.05). Çin malı toksinin injeksiyonundan sonra Kohen ölçütlemesine göre belirgin düşüş gözlendi. Her iki farklı üretim toksininin injeksyonundan sonra 7. gün, 4. hafta, 12. hafta ve 24. haftada bleforaspazm ve hemifasial spazmda belirgin düzelmeler görüldü (p 0.05). SONUÇ: Bleforospazm ve hemifasial spazmda basit bir uygulama ile kullanılan iki farklı Botulinismus toksini arasında etkinlik açısından fark saptanmamıştır

🔖

Cite This Article

WU, C., SHEN, J., CHEN, Y., LIAN, Y. (2011). Blefarospazm ve hemifasiyal spazmda botulinismus toksininin iki farklı formülünün karşılaştırılması. Turkish Neurosurgery, Cilt: 21 - Sayı: 4, 625–629. https://ajindex.com/articles/405087

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Brin MF, Comella C, O Brien C: An interim analysis of the clinical status of patients receiving Current Botox (lot 2024 or subsequent lots) for the treatment of cervical dystonia (CD). Mov Disord 15: 28-29, 2000 2. Cohen DA, Savino P, Stern MB, Hurtig HI: Botulinum injection therapy for blepharospasm: A review and report of 75 patients. Clin Neuropharmacol 9: 415-429, 1986 3. Dressler D: New formulation of BOTOXH: Complete antibodyinduced therapy failure in hemifacial spasm. J Neurol 251:360, 2004 4. Jankovic J, Vuong KD, Ahsan J: Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 60:1186–1188, 2003 5. Quagliato EM, Carelli EF, Viana MA: Prospective, Randomized, Double-Blind Study, Comparing Botulinum Toxins Type A Botox and Prosigne for Blepharospasm and Hemifacial Spasm Treatment. Clin Neuropharm 33: 27-31, 2010 6. Rieder CR, Schestatsky P, Socal MP, Monte TL, Fricke D, Costa J, Picon PD: A double-blind, randomized, crossover study of prosigne versus botox in patients with blepharospasm and hemifacial spasm. Clin Neuropharmacol 30: 39–42, 2007 7. Sampaio C, Costa J, Ferreira JJ: Clinical comparability of marketed formulations of botulinum toxin. Mov Disord 19: 129-136, 2004 8. Tang X, Wan X: Comparison of Botox with a Chinese type A botulinum toxin. Chin Med J 113: 794-798, 2000 9. Wan XH, Tang XF, Wang YC: The properties and longitudinal experience of Chinese Type A botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Chin Med Sci J 18: 254-259, 2003